Identification and clinical value of a new ceRNA axis (TIMP3/hsa‐miR‐181b‐5p/PAX8‐AS1) in thyroid cancer

Abstract

AbstractBackgroundThyroid cancer (TC) is a prevalent and increasingly common malignant tumor. In most cases, TC progresses slowly and runs a virtually benign course. However, challenges remain with the treatment of refractory TC, which does not respond to traditional management or is subject to relapse or metastasis. Therefore, new therapeutic regimens for TC patients with poor outcomes are urgently needed.MethodsThe differentially expressed RNAs were identified from the expression profile data of RNA from TC downloaded from The Cancer Genome Atlas database. Multiple databases were utilized to investigate the regulatory relationship among RNAs. Subsequently, a competitive endogenous RNA (ceRNA) network was established to elucidate the ceRNA axis that is responsible for the clinical prognosis of TC. To understand the potential mechanism of ceRNA axis in TC, location analysis, functional enrichment analysis, and immune‐related analysis were conducted.ResultsA ceRNA network of TC was constructed, and the TIMP3/hsa‐miR‐181b‐5p/PAX8‐AS1 ceRNA axis associated with the prognosis of TC was successfully identified. Our results showed that the axis might influence the prognosis of TC through its regulation of regulating tumor immunity.ConclusionsOur findings provide evidence that TIMP3/hsa‐miR‐181b‐5p/PAX8‐AS1 axis is significantly related to the prognosis of TC. The molecules involved in this axis may serve as novel therapeutic approaches for TC treatment.